Toxic epidermal necrolysis and antifolate drugs in cancer chemotherapy.

[en] Folates are one-carbon donors essential for synthesizing purines, pyrimidines, serine, and methionine. They correspond to anionic hydrophilic molecules essential for DNA synthesis in mammalian cells. The latter cells lack the capacity to synthesize folates. In some patients, high dosages of antifolate drugs (eg: methotrexate, pemetrexed) used in cancer chemotherapy alter the keratinocytes, endothelial cells and Factor XIIIa+ dermal dendrocytes in a range of various severities. Such conditions clinically designed under the heading antifolate cytotoxic skin reaction (ACSR) occasionally resemble the toxic epidermal necrolysis (TEN) / Stevens-Johnson syndrome (SJS) spectrum. Whether or not the TEN/SJS presentation of ACSR is a regular condition similar to that induced by other drugs or a variant condition supported by a unique pathomechanism is unsettled.

Disciplines :

Dermatology

Author, co-author :

Franchimont, Claudine ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques

Lesuisse, Marianne

Humbert, Philippe

Delvenne, Philippe ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques

PIERARD, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Language :

English

Title :

Toxic epidermal necrolysis and antifolate drugs in cancer chemotherapy.

Publication date :

2012

Journal title :

Current Drug Safety

ISSN :

1574-8863

eISSN :

2212-3911

Publisher :

Bentham Science Publishers, United Arab Emirates

Volume :

Issue :

Pages :

357-60

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 01 March 2013

Statistics

Number of views

47 (0 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Pereira F, Mudgil AV, Rosmarin D. Toxic epidermal necrolysis. J Am Acad Dermatol 2007; 56: 181-200.
Paquet P, Piérard GE. New insights in toxic epidermal necrolysis (Lyell's syndrome). Clinical consideration, pathobiology and targeted treatments revisited. Drug Saf 2010; 33: 189-212.
Piérard GE, Paquet P. Facing up to toxic epidermal necrolysis. Exp Opin Pharmacother 2010; 11: 2443-2446.
Downey A, Jackson C, Harun N, Cooper A. Toxic epidermal necrolysis: review of pathogenesis and management. J Am Acad Dermatol, Epub 2011, Dec 9.
Fritsch PO, Sidoroff A. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Clin Dermatol 2000; 1: 349-360.
Khalili B, Bahna S. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis. Ann Allerg Asthma Immunol 2006; 97: 272-281.
Watanabe R, Watanabe H, Sotozono C, et al. Critical factors differentiating erythema multiforme majus from Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN). Eur J Dermatol 2011; 21: 889-894.
Schneider G, Kachroo S, Jones N, et al. A systematic review of validated methods for identifying erythema multiforme major/minor/not otherwise specified. Stenvens-Johnson syndrome, or toxic epidermal necrolysis using administrative and claims data. Pharmacoepidem Drug Saf 2012; 21: 236-239.
Orion E, Matz H, Wolf R. The life-threatening complications of dermatologic therapies. Clin Dermatol 2005; 23: 182-192.
Valeyrie-Allanore L, Roujeau JC. Denominations and classification of severe cutaneous adverse reactions to drugs: splitters versus mergers. Eur J Dermatol 2007; 17: 359-360.
Paul C, Wolkenstein P, Adle H, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996; 134: 710-714.
Paquet P, Piérard GE. Toxic epidermal necrolysis: revisiting the tentative link between early apoptosis and late necrosis. Int J Mol Med 2007; 19: 3-10.
Paquet P, Nikkels A, Arrese JE, et al. Macrophages and tumor necrosis factor-alpha in toxic epidermal necrolysis. Arch Dermatol 1994; 130: 605-608.
Abe R, Shimizu T, Shibaki A, et al. Toxic epidermal necrolysis and tevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 2003; 162: 1515-1520.
Nassif A, Bensussan A, Boumsell L, et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004; 114: 1209-1215.
Paquet P, De Groote D, Piérard GE. Functionally-active macrophage-derived myeloperoxidase in the skin of drug-induced toxic epidermal necrolysis. Dermatology 2010; 220: 201-207.
Tohyama M, Watanabe H, Murakami S, et al. Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 2012; 166: 322-330.
Franchimont C, Piérard GE. Cutaneous pathobiology mediated by chemotherapy. J Cutan Pathol 1980; 7: 387-393.
Reed KM, Sober AJ. Methotrexate-induced necrolysis. J Am Acad Dermatol 1983; 8: 677-679.
Gaigl Z, Seitz CS, Bröcker EB, et al. Methotrexate-induced toxic epidermal necrolysis-like skin toxicity. Eur J Dermatol 2007; 17: 168-169.
Tummino C, Barlesi F, Tchouhadjian C, et al. Severe cutaneous toxicity after pemetrexed as a second line treatment for a refractory non small cell lung cancer. Rev Mal Respir 2007; 24: 635-638.
Sawada Y, Kawakami C, Nakamura M, et al. Toxic epidermal necrosis-like dermatosis induced by the first course of methotrexate. Eur J Dermatol 2009; 19: 397-398.
Hagner N, Joerger M. Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res 2010; 2: 293-301.
Jarmula A. Antifolate inhibitors of thymidylate synthase as anticancer drugs. Mini Rev Med Chem 2010; 10: 1211-1222.
Zhao R, Matherly LH, Goldman ID. Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. Expert Rev Mol Med 2009; 11: e4.
Goldman ID. The characteristics of the membrane transport of amethopterin and the naturally occurring folates. Ann NY Acad Sci 1971; 186: 400-422.
Whetsline JR, Flatley RM, Matherly LH. The human reduced folate carrier gene is ubiquitously and differentially expressed in normal human tissues: identification of seven non-coding exons and characerization of a novel promoter. Biochem J 2002; 367: 629-640.
Chen G, Wright JE, Rosowsky A. Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells. Mol Pharmacol 1995; 48: 758-765.
Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 1994; 73: 2432-2443.
Ross JF, Wang H, Behm FG, et al. Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer 1999; 85: 348-357.
Shen F, Ross JF, Wang X, Ratnam M. Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and itssue specificity. Biochemistry 1994; 33: 1209-1215.
Shen F, Wu M, Ross JF, Miller D, Ratnam M. Folate receptor type gamma is primarily a secretory protein due to lack of an efficient signal for glycosylphosphatidylinositol modification: protein characterization and cell type specificity. Biochemistry 1995; 34: 5660-5665.
Westerhof GR, Schornagel JH, Kathmann I, et al. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. Mol Pharmacol 1995; 48: 459-471.
Pritchard DM, Bower L, Potten CS, et al. The importance of p53-independent apoptosis in the intestinal toxicity induced by raltitrexed (ZD1694, Tomudex): genetic differences between BALB/c and DBA/2 mice. Clin Cancer Res 2000; 6: 4389-4395.
Hind D, Tappenden P, Tumur I, et al. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systemaic review and economic evaluation. Health Technol Assess 2008; 12: 3-9, xi-162.
Surmont VF, van Meerbeeck JP. Raltitrexed in mesothelioma. Expert Rev Anticancer Ther 2011; 11: 1481-1490.
O'Connor OA, Horwitz S, Hamlin P, et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 2009; 27: 4357-4364.
Tynterov AI, Begel NI. Lyell's syndrome from the repeat treatment of psoriasis with methotrexate. Vestn Dermatol Venereol 1988; 6: 46-48.
Cuthbert RJ, Craig JI, Ludlam CA. Stevens-Johnson syndrome associated with methotrexate treatment for non-Hodgkin's lymphoma. Ulster Med J 1993; 62: 95-97.
Primka EJ, Camisa C. Methotrexate-induced toxic epidermal necrolysis in a patient with psoriasis. J Am Acad Dermatol 1997; 36: 815-818.
Hani N, Casper C, Groth W, et al. Stevens-Johnson syndrome-like exanthema secondary to methotrexate histologically simulating acute graft-versus-host disease. Eur J Dermatol 2000; 10: 548-550.
Yang CH, Yang LJ, Jaing TH, Chan HL. Toxic epidermal necrolysis following combination of methotrexate and trimethoprim-sulfamethoxazole. Int J Dermatol 2000; 39: 621-623.
Cakesen H, Oner AF. Toxic epidermal necrolysis in a girl with leukemia receiving methotrexate. Indian Pediatr 2001; 38: 426.
Paquet P, Jacob E, Pirson J, et al. Drug-induced toxic epidermal necrolysis and pancytopenia: a puzzling association. Int J Mol Med 2005; 16: 29-33.
Werchniak AE, Chaffee S, Dinulos JG. Methotrexate-induced bullous acral erythema in a child. J Am Acad Dermatol 2005; 52: S93-S95.
Tezer H, Kuskonmaz B, Kara A, et al. Intravenous immunoglobulin in the treatment of severe methotrexate-induced acral erythema. J Pediatr Hematol Oncol 2008; 30: 391-393.
Paquet P, Quatresooz P, Piérard GE. Factor XIIIa-positive dendrocytes in drug-induced toxic epidermal necrolysis (Lyell's syndrome): paradoxical activation in skin and rarefaction in lymph nodes. Dermatology 2003; 206: 374-376.
Quatresooz P, Piérard GE. Dermal dendrocyte ballooning. Am J Clin Dermatol 2006; 7: 391-392.
Quatresooz P, Paquet P, Hermanns-Lê T, et al. Molecular mapping of Factor XIIIa-enriched dendrocytes in the skin. Int J Mol Med 2008; 22: 403-409.
Niyikiza C, Hanauske AR, Rusthoven JJ, et al. Pemetrexed safety and dosing strategy. Semin Oncol 2002; 29: 24-29.
Dickgreber NJ, Sorensen JB, Paz-Ares LG, et al. Pemetrexedsafety and pharmacokinetics in patients with third-space fluid. Clin Cancer Res 2010; 16: 2872-2880.
Bosch-Barrera J, Gaztanaga M, Ceballos J, et al. Toxic epidermal necrolysis related to pemetrexed and carboplatin with vitamin B12 and folic acid supplementation for advanced non-small cell lung cancer. Onkologie 2009; 32: 580-584.
Piérard-Franchimont C, Quatresooz P, Reginster MA, Piérard GE. Revisiting cutaneous adverse reactions to pemetrexed. Oncol Lett 2001; 2: 769-772.
Sabatiello M, Willemaers V, Lesuisse M, Piérard GE. Pemetrexed-induced pityriasis lichenoides-like dermatitis. J Eur Acad Dermatol Venereol 2012; 26: 127-129.
Kaufman WS, McNamara EK, Curtis AR, et al. Febrile ulceronecrotic Mucha-Habermann disease (pityriasis lichenoides et varioliformis acuta fulminans) presenting as a Stevens-Johnson syndrome. Pediatr Dermatol 2012; 29: 135-140.
Quatresooz A, Rorive P, Paquet P, et al. Cutaneous adverse effects predicting the efficacity of targeted antineoplastic therapies. Rev Med Liège 2009; 64: 347-350.